With the integration of the next-generation ClearSight finger cuff into the EV1000 clinical platform, a single platform can now be utilized with both noninvasive and minimally-invasive hemodynamic monitoring options, such as the FloTrac sensor. The ClearSight system also sends an analog pressure to visualize noninvasive BP on a bedside monitor. Edwards has taken this integrated system approach to protect the accuracy of the clinical information and the corresponding quality of patient care.

Helping to advance the care of the acutely ill for 40 years, Edwards Lifesciences seeks to provide the valuable information you need, the moment you need it. Through continuing collaboration with you, ongoing education and our never-ending quest for advancement, our goal is to delivery clarity in every moment.

References

For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards Lifesciences devices placed on the European market, meet the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC, and bear the CE-marking of conformity.

© 2014 Edwards Lifesciences Corporation. All rights reserved. AR11578
The ClearSight system extends continuous hemodynamic monitoring to a broader patient population, including your moderate to high-risk surgery patients. By leveraging proven ccNexfin system technology, the ClearSight system provides clinicians clarity without the barriers of complexity or invasiveness.

**Simple for clinicians**
The ClearSight system quickly connects to the patient by wrapping an inflatable cuff around the finger. The simplicity of the ClearSight system gives you noninvasive access to automatic, up-to-the-minute hemodynamic information for a broader patient population.

**Leverages validated technology**
Used as the standard for monitoring in space for decades, ccNexfin noninvasive technology (volume clamp, Physiocal) has been extensively validated against gold-standard monitoring technologies. Several studies have validated the ability of noninvasive ccNexfin technology to reliably track continuous blood pressure, absolute cardiac output and continuous cardiac output.

**Advanced hemodynamic monitoring extended to moderate-risk patients**
The ClearSight system enables you to expand advanced hemodynamic monitoring to your moderate to high-risk surgery patients — including elderly or obese patients — enabling you to make more informed decisions regarding volume administration.

Flow parameters provided, such as SV and SVV, have been shown to be more dynamic, and sensitive and specific for predicting fluid responsiveness than conventional, pressure-based parameters. These parameters are central to Perioperative Goal-Directed Therapy (PGDT) protocols and, when used together, are key to guiding optimal volume administration in patients at risk of developing complications.

Noninvasive simplicity. Next-generation clarity.
Edwards Lifesciences ClearSight system is comprised of the ClearSight finger cuff and EV1000 clinical platform. The system presents SV, SVV, CO, SVR and continuous BP clearly and simply on the EV1000 monitor. Easy-to-use touch screens allow selection of the parameters most meaningful for each clinical situation. This intuitive display of fundamental information minimizes unknowns and allows you to more accurately determine your patient’s fluid status.

**Visual clinical support**
Advanced hemodynamic parameters are presented in a visually simplified manner. Color-based indicators communicate patient status at a glance, and visual clinical support screens allow for immediate recognition and increased understanding of rapidly changing clinical situations.

The noninvasive ClearSight system provides valuable hemodynamic insight to an expanded patient population, for making more informed decisions about volume administration in moderate to high-risk surgery. Delivering clarity in every moment.

---

### Historical milestones

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1967</td>
<td>Volume clamp method to measure blood pressure invented by Jan Peñáz</td>
</tr>
<tr>
<td>1977</td>
<td>TNO, a high-profile Dutch research institute, starts development of noninvasive blood pressure</td>
</tr>
<tr>
<td>2005</td>
<td>BMEYE was founded as a spin-off from TNO</td>
</tr>
<tr>
<td>2007</td>
<td>Market introduction of Nexfin system with CO-Trek to non-invasively monitor blood pressure and cardiac output</td>
</tr>
<tr>
<td>2014</td>
<td>Market introduction of ClearSight integrated into the EV1000 clinical platform</td>
</tr>
</tbody>
</table>
The ClearSight system extends continuous hemodynamic monitoring to a broader patient population, including your moderate to high-risk surgery patients. By leveraging proven ccNexfin system technology, the ClearSight system provides clinicians clarity without the barriers of complexity or invasiveness.

Simple for clinicians
The ClearSight system quickly connects to the patient by wrapping an inflatable cuff around the finger. The simplicity of the ClearSight system gives you noninvasive access to automatic, up-to-the-minute hemodynamic information for a broader patient population.

Leverages validated technology
Used as the standard for monitoring in space for decades, ccNexfin noninvasive technology (volume clamp, Physiocal) has been extensively validated against gold-standard monitoring technologies. Several studies have validated the ability of noninvasive ccNexfin technology to reliably track continuous blood pressure, absolute cardiac output and continuous cardiac output.

Advanced hemodynamic monitoring extended to moderate-risk patients
The ClearSight system enables you to expand advanced hemodynamic monitoring to your moderate to high-risk surgery patients — including elderly or obese patients — enabling you to make more informed decisions regarding volume administration.

Flow parameters provided, such as SV and SVV, have been shown to be more dynamic, and sensitive and specific for predicting fluid responsiveness than conventional, pressure-based parameters. These parameters are central to Perioperative Goal-Directed Therapy (PGDT) protocols and, when used together, are key to guiding optimal volume administration in patients at risk of developing complications.

The noninvasive ClearSight system provides valuable hemodynamic insight to an expanded patient population, for making more informed decisions about volume administration in moderate to high-risk surgery. Delivering clarity in every moment.

Historical milestones

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1967</td>
<td>Volume clamp method to measure blood pressure invented by Jan Peñáz</td>
</tr>
<tr>
<td>1977</td>
<td>TNO, a high-profile Dutch research institute, starts development of noninvasive blood pressure</td>
</tr>
<tr>
<td>2005</td>
<td>BM&amp;EYE was founded as a spin-off from TNO</td>
</tr>
<tr>
<td>2007</td>
<td>Market introduction of Nexfin system with CO-Trek to non-invasively monitor blood pressure and cardiac output</td>
</tr>
<tr>
<td>2014</td>
<td>Market introduction of ClearSight integrated into the EV1000 clinical platform</td>
</tr>
</tbody>
</table>
Know More.

With the integration of the next-generation ClearSight finger cuff into the EV1000 clinical platform, a single platform can now be utilized with both noninvasive and minimally-invasive hemodynamic monitoring options, such as the FloTrac sensor. The ClearSight system also sends an analog pressure to visualize noninvasive BP on a bedside monitor. Edwards has taken this integrated system approach to protect the accuracy of the clinical information and the corresponding quality of patient care.

Helping to advance the care of the acutely ill for 40 years, Edwards Lifesciences seeks to provide the valuable information you need, the moment you need it. Through continuing collaboration with you, ongoing education and our never-ending quest for advancement, our goal is to delivery clarity in every moment.

References


For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices placed on the European market, meet the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC, and bear the CE marking of conformity. Edwards, Edwards Lifesciences, the stylized E logo, ccNexfin, ClearSight, EV1000, FloTrac and Nexfin are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. © 2014 Edwards Lifesciences Corporation. All rights reserved. AR1578